Hyloris Pharmaceuticals SA 2024 AR2
The report highlights Hyloris Pharmaceuticals' significant progress in 2024, with total revenue and other income surpassing ’10 million, driven by increased royalties and milestone payments. The company successfully launched Maxigesic IV in the U.S. and received approval for Podofilox Gel, the first generic alternative to Condylox Gel. Hyloris expanded its pipeline with two new product candidates in 2024 and three more in early 2025, targeting 30 assets by the end of 2025. On the ESG front, the company voluntarily aligned its disclosures with the European Sustainability Reporting Standards (ESRS) and continued its transition to a sustainable vehicle fleet.
Company: Hyloris Pharmaceuticals SA
Sector: Manufacturing
Country: Belgium
Year: 2024
Type: AR2
Pages: 195
Back to company
Hyloris Pharmaceuticals SA
Annual Report
The report highlights Hyloris Pharmaceuticals' significant progress in 2024, with total revenue and other income surpassing ’10 million, driven by increased royalties and milestone payments. The company successfully launched Maxigesic IV in the U.S. and received approval for Podofilox Gel, the first generic alternative to Condylox Gel. Hyloris expanded its pipeline with two new product candidates in 2024 and three more in early 2025, targeting 30 assets by the end of 2025. On the ESG front, the company voluntarily aligned its disclosures with the European Sustainability Reporting Standards (ESRS) and continued its transition to a sustainable vehicle fleet.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Workplace Fatalities
Employees